GlassScriptPhysician profile
Emma M Sullivan
NPI 1447924055
$11,730.97
in general payments reported to CMS, 2019-2025
40 companies · $3,246 in 2025
The $3,246 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $1,818 · 2023: $2,411 · 2024: $3,976 · 2025: $3,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,633.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,930.46 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,312.20 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $878.19 | 2021-2025 | Emgality, Mounjaro, Amyvid |
| Pfizer INC. | $542.57 | 2023-2025 | |
| Ucb, INC. | $535.39 | 2022-2025 | Nayzilam, Briviact, Zilbrysq |
| Neurelis, INC. | $475.95 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $423.95 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $412.19 | 2022-2025 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $335.84 | 2023-2025 | Fycompa |
| Ironshore Pharmaceuticals INC. | $318.02 | 2021-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $285.42 | 2024-2025 | Qelbree |
| Eisai INC. | $282.30 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $217.49 | 2025 | Jornay Pm |
| Tris Pharma INC | $202.86 | 2022-2025 | Dyanavel Xr |
| Sumitomo Pharma America, INC. | $196.30 | 2023-2024 | Aptiom |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.